MedTrace Logo

Diffusion-Weighted MRI for Liver Metastasis

NCT02781935 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 233

Last updated 2024-01-05

No results posted yet for this study

Summary

The DREAM study will assess the diagnostic accuracy of diffusion-weighted MRI in combination with other imaging modalities (multiparametric MRI and CT Scan) in determining the true status of disappearing liver metastasis (DLM) detected after conversion systemic therapy for unresectable or borderline resectable colorectal liver metastasis (CRLM).

Conditions

  • Colorectal Cancer
  • Colon Cancer Liver Metastasis
  • Malignant Neoplasm of Rectum Metastatic to Liver

Interventions

PROCEDURE

DW-MRI

DW-MRI combined with Contrast Enhanced MRI will be used to confirm the status of disappearing liver metastasis prior to surgery and will be compared to findings from either histopathology of resected lesions (Rubbia-Brandt Classification of Tumor regression grading) or follow-up imaging of lesions left behind (either CT scan or MRI) after surgery. MRI will be used during the follow-up period to confirm recurrences from a previous site of DLM.

Sponsors & Collaborators

  • Japan Clinical Oncology Group

    collaborator OTHER

  • European Society of Surgical Oncology

    collaborator OTHER

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Serge Evrard · Institut Bergonie, France

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2023-09-27
Completion
2023-09-27

Countries

  • United States
  • Austria
  • Belgium
  • France
  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02781935 on ClinicalTrials.gov